Activation of HER3 interferes with antitumor effects of axl receptor tyrosine kinase inhibitors: Suggestion of combination therapy

Neoplasia (United States)

Volumn 16, Issue 4, 2014, Pages 301-318

  Torka, Robert ^a   Pénzes, Kinga ^a,c   Gusenbauer, Simone ^a   Baumann, Christine ^a   Szabadkai, István ^b   Orfi, Lászlo ^b,c   Kéri, György ^b,c   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b Vichem Chemie Research Ltd   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; BMS 777607; DSB MPCD 84111; DSB R 428; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; MPCD 84111; NEU DIFFERENTIATION FACTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIGAND; MYELIN PROTEIN; ONCOPROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RTN4R PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; NEOPLASMS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; LIGANDS; MICE; MYELIN PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, CELL SURFACE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84903948758     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.03.009     Document Type: Article

References (54)

1. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa III R, Le Beau MM, Earp HS, and Liu ET. (1991). axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11, 5016-5031.
2. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, and Bartram CR. (1991). A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6, 2113-2120.
3. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C,Mattsson K, Fisher J, Gies DR, and Jones PF, et al. (1995). The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80, 661-670.
4. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, and Toso RJ, et al. (1995). Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrestspecific gene 6. Nature 373, 623-626.
5. Hafizi S and Dahlbäck B (2006). Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 17, 295-304.
6. Linger RM, Keating AK, Earp HS, and Graham DK. (2008). TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100, 35-83.
7. Verma A, Warner SL, Vankayalapati H, Bearss DJ, and Sharma S. (2011). Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10, 1763-1773.
8. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, and Wu CW. (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7, 1058-1064.
9. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB, and Wang H. (2011). Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117, 734-743.
10. Koorstra JB, KarikariCA, Feldmann G, Bisht S,Rojas PL,Offerhaus GJ, Alvarez H, andMaitra A. (2009). The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8, 618-626.
11. Vajkoczy P, Knyazev P, Kunkel A, CapelleHH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, and Read TA, et al. (2006). Dominantnegative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 103, 5799-5804.
12. Chen PX, Li QY, and Yang Z. (2013). Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann Diagn Pathol 17, 425-429.
13. Byers LA,Diao L,Wang J, Saintigny P,Girard L, PeytonM, Shen L, Fan Y, Giri U, and Tumula PK, et al. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19, 279-290.
14. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, and Gjertsen BT, et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107, 1124-1129.
15. Gustafsson A, Martuszewska D, JohanssonM, Ekman C, Hafizi S, Ljungberg B, and Dahlbäck B. (2009). Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15, 4742-4749.
16. HuttererM, Knyazev P, Abate A, ReschkeM,Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, and Muigg A, et al. (2008). Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14, 130-138.
17. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, and Neubauer A. (1999). Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13, 1352-1358.
18. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, and Langdon SP. (2005). Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 65, 6789-6800.
19. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, and Chuang SE. (2008). Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268, 314-324.
20. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, and Gilmer TM. (2009). Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69, 6871-6878.
21. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, and Garewal H, et al. (2007). A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26, 3909-3919.
22. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, and Auberger P. (2011). Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874-885.
23. Zhang Z, Lee JC, Lin L,Olivas V, Au V, Laframboise T, Abdel-RahmanM,Wang X, Levine AD, and Rho JK, et al. (2012). Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44, 852-860.
24. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A, and Henley B, et al. (2009). Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 52, 1251-1254.
25. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, and Heckrodt TJ, et al. (2010). R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70, 1544-1554.
26. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, and Pei L. (2009). Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442-3455.
27. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, and Caplen NJ. (2011). Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130, 663-679.
28. Campbell MR, Amin D, and Moasser MM. (2010). HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16, 1373-1383.
29. Révillion F, Lhotellier V, Hornez L, Bonneterre J, and Peyrat JP. (2008). ErbB/ HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19, 73-80.
30. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, and Rosen N. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71.
31. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, and Arteaga CL. (2012). Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 109, 2718-2723.
32. Myatt SS and Lam EW (2007). The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7, 847-859.
33. Hynes NE and Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354.
34. Stern DF (2008). ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13, 215-223.
35. Blobel CP (2005). ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6, 32-43.
36. Borrell-PagèsM, Rojo F, Albanell J, Baselga J, and Arribas J. (2003).TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 22, 1114-1124.
37. Dong J, Opresko LK, Dempsey PJ, Lauffenburger DA, Coffey RJ, and Wiley HS. (1999).Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A 96, 6235-6240.
38. Engelman JA and Settleman J (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18, 73-79.
39. ParsaAT,WaldronJS,PannerA,CraneCA, Parney IF, Barry JJ, CacholaKE,Murray JC, Tihan T, and JensenMC, et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13, 84-88.
40. Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, and Mayo LD. (2009). PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle 8, 896-901.
41. Paccez JD, Vogelsang M, Parker MI, and Zerbini LF. (2014). The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer 134, 1024-1033.
42. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, and Zarrinkar PP. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29, 1046-1051.
43. Hölzel M, Bovier A, and Tüting T. (2013). Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13, 365-376.
44. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, and Sone S, et al. (2009). Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 15, 6630-6638.
45. Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Högel B, Eiermann W, Knyazev P, and Ullrich A. (2013). Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 13, 197.
46. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, and Levy RB, et al. (1992). Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69, 559-572.
47. Nagata K, Wada K, Tatsuguchi A, Futagami S, Gudis K, Miyake K, Tsukui T, and Sakamoto C (2006). Heregulin-α and heregulin-β expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 290, G1243-G1251.
48. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, and Sawyer DB. (2005). Neuregulin-1α and β isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 311, 135-146.
49. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, and Russell KS. (2011). Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 123, 2254-2262.
50. Miyazaki Y, Nakanishi Y, and Hieda Y. (2004). Tissue interaction mediated by neuregulin-1 and ErbB receptors regulates epithelial morphogenesis of mouse embryonic submandibular gland. Dev Dyn 230, 591-596.
51. Mograbi B, Rochet N, Imbert V, Bourget I, Bocciardi R, Emiliozzi C, and Rossi B. (1997). Human monocytes express amphiregulin and heregulin growth factors upon activation European cytokine network. Eur Cytokine Netw 8, 73-81.
52. De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, and Braems G, et al. (2013). Bone marrowderived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 62, 550-560.
53. Shibuya M, Komi E, Wang R, Kato T, Watanabe Y, Sakai M, Ozaki M, Someya T, and Nawa H. (2010). Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. J Neural Transm 117, 887-895.
54. Lee CY, Lin Y, Bratman S, Feng W, Kuo A, Scheeren F, Engreitz JM, Varma S, West R, and Diehn M. (2013). Neuregulin autocrine signaling promotes selfrenewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 74, 341-352.